A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma - Concepedia

Concepedia

Publication | Closed Access

A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

126

Citations

31

References

2014

Year

Wolfgang Wick, Harald Fricke, Klaus Junge, Grigory Kobyakov, Tobias Martens, Oliver Heese, Benedikt Wiestler, Maximilian G. Schliesser, Andreas von Deimling, Josef Pichler,

Clinical Cancer Research

Abstract

CD95 pathway inhibition in combination with rRT is an innovative concept with clinical efficacy. It warrants further clinical development. CD95L promoter methylation in the tumor may be developed as a biomarker.

References

	Year	Citations

Page 1